summary: In a world of addictive foods, GLP-1 medications are emerging as a revolutionary tool for combating obesity and its related health issues. Dr. David A. Kessler, a former FDA commissioner, discusses his personal and professional insights into the obesity epidemic, emphasizing the role of ultra-processed foods in triggering addictive brain pathways. While GLP-1 drugs show promise in reducing weight and improving health markers, they are not a standalone solution. Challenges include affordability, side effects, and the lack of long-term studies on their use. Dr. Kessler advocates for comprehensive strategies, including better dietary guidance, behavioral changes, and confronting the food industry's role in the crisis.